fetching data ...

POS1299 (2021)
RISK FACTORS OF TOTAL HIP ARTHROPLASTY IN JUVENILE ARTHRITIS WITH HIP INVOLVEMENT
L. Sorokina1, I. Avrusin1, R. Raupov1, N. Garipova2, M. Gharabaghtsyan3, S. Khrypov4, E. Isupova1, E. Gaidar1, I. Chikova1, M. Dubko1, V. Masalova1, T. Likhacheva1, L. Snegireva1, M. Kostik1,5
1Saint-Petersburg State Pediatric Medical University, Department of Hospital Pediatrics, St. Petersburg, Russian Federation
2Almazov National Medical Research Centre, Pediatric Department, St. Petersburg, Russian Federation
3Institute of Child and Adolescent Health (ICAH) with the Arabkir Medical Center, Pediatric Department, Yerevan, Armenia
4Saint-Petersburg Clinical Research-Practical Center for Specialized Healthcare (Oncology), Surgical Department, St. Petersburg, Russian Federation
5Almazov National Medical Research Centre, Autoimmune and Autoinflammatory Diseases, St. Petersburg, Russian Federation

Background: Hip osteoarthritis (HOA) is a severe outcome of juvenile idiopathic arthritis (JIA) itself and also can be result of corticosteroid (CS) treatment, if it was used. Total hip arthroplasty (THA) is the last step in JIA treatment and indicates ineffectiveness of conservative treatment.


Objectives: We aimed to evaluate risk factors which lead to THA in JIA patients with HOA.


Methods: 753 patients aged 2-17 years were included in our retrospective study during the last 10 years. Diagnosis was made according to ILAR criteria. Clinical, laboratory and radial examinations were evaluated. Diagnosis of HOA was made on MRI, CT and planar radiograms and confirmed by morphological examination of removed femoral heads.


Results: Total 153/753 (20.3%) patients with JIA had hip involvement. HOA developed in 48/153 (31.4%) of JIA patients and 16/48 (33.3%) of them had THA was undergone. Prevalence of HOA and THA (%) in JIA subtypes: in polyarticular (5/32 (15.6%) and 8/16 (50%), systemic (6/32 (18.7%) and 5/16 (31.2%)), enthesitis-related (19/32 (59.4%) and 3/16 (18.8%)) and psoriatic (2/32 (6.7%) and 0/16) subtypes respectively, р=0,0000001. Patients who underwent THA initially had higher level of inflammation: elevated ESR (33 vs 5 mm/h, p=0.002) and CRP (14.7 vs 1.9 mg/l, p=0.03), more active joint, and especially involvement of joints of upper limbs: elbows (p=0.004) and proximal interphalangeal joints (p=0.001), arthritis of subtalar joint (p=0.02). Delayed biologic treatment (7.5 vs 3.4 years, p=0.043) and delayed achievement of remission (9.2 vs 5.6 years, p=0.047) were main predictors of THA. Patients with HOA without biologics had increased cumulative probability of THA: HR=1.99 (1.01; 3.98), p=0.049 ( Figure 1 ). Patients with THA received corticosteroids (93.7 vs 50%, p=0.003) more often including high dose pulse-therapy regimes, but differences in the cumulative doses were not observed (5000 vs 4500 mg, p=0.54) between groups, CS administration was independent risk factor of HOA and THA.

Cumulative probability of THA in JIA patients with hip osteoarthritis.


Conclusion: the main risk factors of THA are systemic and polyarticular course because of their activity, systemic CS and delayed biologic treatment. Corticosteroids should be avoided in those group of patients because of risk of avascular pathway HOA formation.

This work supported by the Russian Foundation for Basic Research (grant № 18-515-57001).

The features of JIA patients with hip osteoarthritis depending on

JIA features THA, (n=16) HOA without THA, (n=32) p
Time to THA, years 5.2 (3.6; 10.2) 4.6 (2.2; 8.7) 0.4
Onset age, years 7.95 (3.5; 11.1) 8.3 (4.3; 13.1) 0.5
JIA duration, years 8.5 (6.5; 13.2) 5.43 (2.8; 11.1) 0.07
Polyarticular JIA, n (%) 8 (50.0) 5 (15.6) 0.037
Systemic JIA, n (%) 5 (31.3) 6 (7.0) 0.037
ANA, n (%) 3/8 (37.5) 5/16 (31.3) 0.760
HLA B27, n (%) 3/6 (50) 9/19 (47.4) 0.911
RF, n (%) 0/9 (0) 1/15 (6.7) 0.429
Uveitis, n (%) 1/16 (6.3) 3/24 (12.5) 0.519
ESR, mm/h 33 (13; 54) 5 (3; 27) 0.002
CRP, mg/l 14.7 (2.9; 72.3) 1.9 (0.3; 12.7) 0.03
Active joints, n 21.5 (8.5; 52.5) 9 (5; 16) 0.02
Elbows, n (%) 11 (68.7) 8 (25.0) 0.004
Proximal interphalangeal joints, n (%) 10 (62.5) 5 (15.6) 0.001
Subtalar, n(%) 4 (25.0) 1 (3.1) 0.02
Pulse-therapy GCS, n(%) 11 (68.7) 10 (31.3) 0.014
Cumulative GCS dose, mg 5000 (3000; 14000) 4500 (500; 20000) 0.54
Time to biologic, years 7.6 (4.3; 11.4) 3.4 (1.9; 8.6) 0.04
Achievement of remission, years 9.2 (6.6; 15.4) 5.6 (3.3; 11.4) 0.047

Disclosure of Interests: None declared

Citation: Ann Rheum Dis, volume 80, supplement 1, year 2021, page 931
Session: Paediatric rheumatology (POSTERS only)